Antitumor Activity and Pharmacokinetics in Mice of 8-Carbamoyl-3-methyl-imidazo[5, 1-d], 2, 3, 5-tetrazin-4(3/f)-one (CCRG 81045; M & B 39831), a Novel Drug with Potential as an Alternative to Dacarbazine

Cancer Research

Volumn 47, Issue 22, 1987, Pages 5846-5852

  Stevens, Malcolm F G ^a   Hickman, John A ^a   Langdon, Simon P ^a   Chubb, David ^a   Vickers, Lisa ^a   Stone, Robert ^a   Baig, Ghousia ^a   Goddard, Colin ^a   Gibson, Neil W ^a   Slack, John A ^a   Newton, Christopher ^b   Lunt, Edward ^b   Fizames, Christian ^c   Lavelle, Francois ^c  

^a ASTON UNIVERSITY   (United Kingdom)

^b May and Baker Limited   (United Kingdom)

^c SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DACARBAZINE; MITOZOLOMIDE DERIVATIVE; NEW DRUG; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; CANCER CHEMOTHERAPY; DRUG HALF LIFE; LEUKEMIA; LYMPHOMA; MELANOMA B16; MOUSE; NONHUMAN; STRUCTURE ACTIVITY RELATION;

ANIMAL; ANTINEOPLASTIC AGENTS; COMPARATIVE STUDY; DACARBAZINE; IMIDAZOLES; LUNG NEOPLASMS; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED CBA; MICE, INBRED DBA; MICE, INBRED STRAINS; NEOPLASMS, EXPERIMENTAL; PLASMACYTOMA; SARCOMA, EXPERIMENTAL; SPECIES SPECIFICITY; SUPPORT, NON-U.S. GOV'T;

EID: 0023605735     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Baig, G. U., and Stevens, M. F. G. Antitumor imidazotetrazines. 12. Reactions of mitozolomide and its 3-alkyl congeners with oxygen, nitrogen, halogen and carbon nucleophiles. J. Chem. Soc. Perkin Trans. 1, 665–670, 1987.
2. Stevens, M. F. G., Hickman, J. A., Stone, R., Gibson, N. W., Lunt, E., Newton, C. G., and Baig, G. U. Antitumor imidazotetrazines. 1. Synthesis and chemistry of 8-carbamoyl-3-(2-chloroethyl)imidazo[5, l-d]-1, 2, 3, 5-tetrazin-4(3H)-one, a novel broad-spectrum antitumor agent. J. Med. Chem., 27: 196–201, 1984.
3. Lowe, P., Schwalbe, C. H., and Stevens, M. F. G. Antitumor imidazotetrazines. 5. Crystal and molecular structure of 8-carbamoyl-3-(2-chloroethyl)imidazo[5, l-d]-l, 2, 3, 5-tetrazin-4(3H)one. J. Chem. Soc. Perkin II, 357–361, 1985.
4. Gibson, N. W., Erickson, L. C., and Hickman, J. A. Effects of antitumor agent 8-carbamoyl-3-(2-chloroethyl)imidazo[5, 1-d]-1, 2, 3, 5-tetrazin-4(3H)-one on the DNA of mouse L1210 cells. Cancer Res., 44:1767-1771, 1984.
5. Gibson, N. W., Hickman, J. A., and Erickson, L. C. DNA cross-linking and cytotoxicity in normal and transformed human cells treated in vitro with 8-carbamoyl-3-(2-chloroethyl)imidazo[5, 1-d]-1, 2, 3, 5-tetrazin-4(3H)one. Cancer Res., 44: 1772-1775, 1984.
6. Horgan, C. M. T., and Tisdale, M. J. Antitumor imidazotetrazines. 4. An investigation into the mechanism of antitumor activity of a novel and potent antitumor agent CCRG 81010 (M & B 39565, NSC 353451). Biochem. Pharmacol., 33:2185-2192, 1984.
7. Horgan, C. M. T., and Tisdale, M. J. Antitumor imidazotetrazines-VIII. Uptake and decomposition of a novel antitumor agent mitozolomide (CCRG 81010; M & B 39565; NSC 353451) in TLX5 mouse lymphoma in vitro. Biochem. Pharmacol., 34:217-221, 1985.
8. Hickman, J. A., Stevens, M. F. G., Gibson, N. W., Langdon, S. P., Fizames, C., Lavelle, F., Atassi, G., Lunt, E., and Tilson, R. M. Experimental antitumor activity against murine model systems of 8-carbamoyl-3-(2-chloroethyl)imidazo(5, l-D)-l, 2, 3, 5-tetrazin-4(3H)-one (mitozolomide), a novel broad-spectrum agent. Cancer Res., 45:3008-3013, 1985.
9. Fodstad, O., Aamdal, S., Pihl, A., and Boyd, M. R. Activity of mitozolomide (NSC 353451), a new imidazotetrazine, against xenografts from human melanomas, sarcomas and lung and colon carcinomas. Cancer Res., 45: 1778–1786, 1985.
10. Newland, E. S., Blackledge, A., Slack, J. A., Goddard, C., Brindley, C. J., Holden, L., and Stevens, M. F. G. Phase 1 clinical trial of mitozolomide. Cancer Treat. Rep., 69:801-805, 1985.
11. Loo, T. L. Triazenoimidazole derivatives. In: A. C. Sartorelli and D. G. Johns (eds.), Antineoplastic and Immunosuppressive Agents, Part 2, pp. 553–554. Berlin: Springer-Verlag, 1975.
12. Comis, R. L., and Carter, S. K. Integration of chemotherapy in the combined modality treatment of solid tumours. II. Malignant melanoma. Cancer Treat. Rev., 1: 284–304, 1974.
13. Hill, G. J., II, Krementz, E. T., and Hill, H. Z. Dimethyl triazeno carboxamide and combination therapy for melanoma. IV. Late results after complete response to chemotherapy (Central Oncology Group Protocols 7130, 7131 and 7131A). Cancer (Phila.), 53:1299-1305, 1984.
14. Bonadonna, G., Zucali, R., and Monfardini, S. Combination chemotherapy of Hodgkins' disease with Adriamycin, bleomycin, vinblastine and imidazole carboxamide vs. MOPP. Cancer (Phila.), 36:252-259, 1975.
15. Gottlieb, J. A., O'Bryan, R. M., Moon, T. E., Bodey, G. P., Sinkobics, J. G., Phigpen, T., and Rivkin, S. E. Improved survival with Adriamycin combinations versus Adriamycin alone in patients with metastatic sarcomas. Proc. Am. Assoc. Cancer Res., 16:238, 1975.
16. Rutty, C. J. The species dependent pharmacokinetics of DTIC. Br. J. Cancer, 48:140, 1983.
17. Shealy, F. Y., and Krauth, D. A. Imidazoles II. 5 (or 4)-Carboxamides. J. Med. Chem., 9:34-38, 1966.
18. Litchfield, J. T., and Wilcoxon, F. A simplified method of evaluating dose-effect experiments. J. Pharmacol. Exp. Ther., 96:99-113, 1949.
19. Slack, J. A., and Goddard, C. Antitumor imidazotetrazines VII. Quantitative analysis of mitozolomide in biological fluids by high performance liquid chromatography. J. Chromatog., 337:178-181, 1985.
20. Goddard, C., Slack, J. A., and Stevens, M. F. G. Antitumour imidazotetrazines, part IX. The pharmacokinetics of mitozolomide in mice. Br. J. Cancer, 52:37-41, 1985.
21. Audette, R. C. S., Connors, T. A., Mandel, H. G., Menu, K., and Ross, W. C. J. Studies on the mechanism of action of the tumour inhibitory triazenes. Biochem. Pharmacol., 22:1855-1864, 1973.
22. Connors, T. A., and Hare, J. R. Studies on the mechanism of action of the tumour-inhibitory nitrosoureas. Biochem. Pharmacol., 24:2133-2140, 1976.
23. Schabel, F. M., Jr. Nitrosoureas: a review of experimental antitumor activity. Cancer Treat. Rep., 60:665-698, 1976.
24. Gibson, N. W., and Hickman, J. A. The role of isocyanates in the toxicity of antitumour haloalkylnitrosoureas. Biochem. Pharmacol., 31: 2795–2800, 1982.
25. Gibson, N. W., Hartley, J., La FrancerR. J., and Vaughan, K. Differential cytotoxicity and DNA-damaging effects produced in human cells of the Mer+ and Mer” phenotypes by a series of alkyltriazinylimidazoles. Carcinogenesis (Lond.), 7; 259–265, 1986.
26. Gescher, A., Hickman, J. A., Simmonds, R. J., Stevens, M. F. G., and Vaughan, K. Studies on the mode of action of antitumour triazenes and triazines—II. Investigation of the selective toxicity of 1-aryl-3, 3-dimethyltriazenes. Biochem. Pharmacol., 30:89-93, 1981.
27. Farina, P., Gescher, A., Hickman, J. A., Horton, J. K., D'lncalci, M., Ross, D., Stevens, M. F. G., and Torti, L. Studies of the mode of action of antitumour triazenes and triazines—IV. The metabolism of l-(4-acetyl-phenyl)-3, 3-dimethy!triazene. Biochem. Pharmacol., 31:1887-1892, 1982.
28. Cheng, C. C., Elslager, E. F., Werbel, L. M., Priebe, S. R., and Leopold, W. R. III. Pyrazole derivatives. 5. Synthesis and antineoplastic activity of 3-(2-chloroethyl)-3, 4-dihydro-4-oxopyrazolo[5, 1-d]-1, 2, 3, 5-tetrazine-8-carboxamide and related compounds. J. Med. Chem., 29: 1544-1547, 1986.